There is an increasing understanding that chromosomal abnormalities play a major role in the pathogenesis of multiple ... cytogenetic composition will be an integral part of the evaluation of ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

We fully agree with Gozzetti and colleagues regarding the importance of cytogenetic testing for prognostication in myeloma. Approximately 15–20% of all myeloma patients present with high-risk ...

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive ...

Medscape Medical News, May 10, 2012 Cytogenetics Predict Long-Term Survival With Multiple Myeloma Cytogenetic abnormalities have a significant impact on long-term survival in patients with ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

Multiple myeloma, historically treated as a single ... Advances in molecular testing, such as cytogenetic analysis of plasma cells, have allowed clinicians to stratify patients based on risk ...

announce that groundbreaking data on the Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma will be presented during the upcoming American Society ...

Cytogenetic results revealed that 64% of ... robust evidence for this strategy after salvage HSCT in relapsed multiple myeloma. Unlike the GMMG ReLApsE study, which found no PFS benefit for ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...